Skip to main content
. 2023 Apr 8;18:100384. doi: 10.1016/j.iotech.2023.100384

Figure 5.

Figure 5

Randomized, double-blind, placebo-controlled study of single ascending oral doses of IOA-289. Healthy male volunteers were administered a single dose of IOA-289 in a capsule formulation (six active subjects per cohort, placebo not analyzed), at increasing dose levels. Plasma exposure of IOA-289 was measured up to 24 h after dose (A). LPA C18:2 in plasma was measured at baseline and up to 24 h after dose; data are % inhibition of baseline levels (B). Using the pharmacokinetic and pharmacodynamic data, the IC50 of IOA-289 was calculated as 15 ng/ml in human plasma (C).

LPA, lysophosphatidic acid.